Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

TLX stock hub

Telix Pharmaceuticals Limited has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

TLXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

3.6B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

TLX

In the news

Latest news · TLX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E530.1

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-1.9

P25 -105.6P50 -46.5P75 -3.1

ROIC2.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All TLX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

201

Groups with data

Currency

USD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0002007191
Company name	Telix Pharmaceuticals Limited
Country	Australia
Country code	US
Employees	1,184
Employees Change	950%
Employees Change Percent	406
Enterprise value	$4B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US87961M1053
Last refreshed	2026-05-10
Market cap	$3.6B
Market cap category	Mid-Cap
Price	$10.68
Price currency	USD
Rev Per Employee	678,880.07x
Sector	Healthcare
Sic	2834
Symbol	TLX
Website	https://telixpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-0.2%
EV/EBIT	206.1x
EV/EBITDA	122.46x
EV/Sales	4.95x
FCF yield	-1.19%
Forward P/E	530.13x
P/B ratio	8.72x
P/S ratio	4.51x
PE Ratio3 Y	496.87x
PE Ratio5 Y	409x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	2.4%
EBITDA Margin	4.04%
Gross margin	47.51%
Gross Profit	$381.8M
Gross Profit Growth	19.52%
Gross Profit Growth Q	65.96%
Gross Profit Growth3 Y	80.88%
Gross Profit Growth5 Y	174.27%
Net Income	$-7.1M
Net Income Growth Years	0%
Pretax Margin	-0.66%
Profit Margin	-0.89%
Profit Per Employee	$-6,018
ROA	1.15
Roa5y	-9.35
ROCE	2.07
ROE	-1.85
Roe5y	-86.68
ROIC	2.6

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-39.85%
EPS Growth Years	0
Revenue Growth	55.61x
Revenue Growth Q	49.29x
Revenue Growth Years	3x
Revenue Growth3 Y	94.75x
Revenue Growth5 Y	188.5x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.76
Assets	$1.2B
Cash	$141.9M
Current Assets	$330.3M
Current Liabilities	$231.6M
Debt	$467.1M
Debt EBITDA	$11.61
Debt Equity	$1.12
Equity	$415.4M
Interest Coverage	1.4
Liabilities	$748.6M
Long Term Assets	$833.7M
Long Term Liabilities	$517M
Net Cash	$-325.2M
Net Cash By Market Cap	$-8.98
Net Debt EBITDA	$10.02
Net Debt Equity	$0.78
Tangible Book Value	$-177.4M
Tangible Book Value Per Share	$-0.52
WACC	7

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.43
Inventory Turnover	13.9
Net Working Capital	$-24.6M
Quick ratio	1.21
Working Capital	$98.7M
Working Capital Turnover	$11.12

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.12%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-39.83%
200-day SMA	9.45
50-day SMA	9.37
50-day SMA vs 200-day SMA	50under200
All Time High	30.36
All Time High Change	-64.82%
All Time High Date	2025-02-24
All Time Low	6.28
All Time Low Change	70.06%
All Time Low Date	2026-02-17
ATR	0.33
Beta	0.61
Ch YTD	42.59
High	10.86
High52	18.49
High52 Date	2025-06-12
High52ch	-42.24%
Low	10.64
Low52	6.28
Low52 Date	2026-02-17
Low52ch	70.06%
Ma50ch	13.97%
Price vs 200-day SMA	12.97%
RSI	56.57
RSI Monthly	39.63
RSI Weekly	57.96
Sharpe ratio	-0.66x
Sortino ratio	-0.84
Total Return	2.12%
Tr YTD	42.59
Tr1m	10.9%
Tr1w	-5.15%
Tr3m	50.42%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	4
Analyst Count Top	2
Analyst Price Target Top	$21
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Operating Income	$19.3M
Operating Income Growth	-65.49
Operating Income Growth Q	-43.59
Operating margin	2.4
Price target	$21.13
Price Target Change	$97.85
Price Target Change Top	$96.63

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	272,834,866%
Float Percent	80.54%
Net Borrowing	-5,527,000
Shares Insiders	14.9%
Shares Institutions	46.53%
Shares Out	338,777,319
Shares Qo Q	0.4%
Shares Yo Y	-2.12%
Short Float	0.14%
Short Ratio	1.53
Short Shares	0.12

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-62.3M
Average Volume	195,029.4x
Bv Per Share	1.23
CAPEX	$-25.7M
Ch1m	10.9
Ch1w	-5.15
Ch1y	-39.83
Ch3m	50.42
Ch6m	9.99
Change	0.19%
Change From Open	-0.09
Close	10.66
Days Gap	0.28
Depreciation Amortization	13,173,000
Dollar Volume	2,125,619
Earnings Date	2026-08-19
EBIT	$19.3M
EBITDA	$32.5M
EPS	$-0.02
F Score	1
FCF	$-43M
FCF EV Yield	-1.08x
FCF Per Share	$-0.13
Financing CF	-3,719,000
Fiscal Year End	December
Founded	2,015
Goodwill	198,988,000
Income Tax	$1.9M
Investing CF	-285,921,000
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-02-19
Last Report Date	2025-12-31
Last Split Type	Never
Last10k Filing Date	2026-02-20
Ma150	8.95
Ma150ch	19.4%
Ma20	10.72
Ma20ch	-0.33%
Net CF	-298,133,000
Next Earnings Date	2026-08-19
Open	10.69
Optionable	No
Position In Range	18.18
Post Close	10.68
Postmarket Change Percent	-0.09
Postmarket Price	$10.67
Ppne	115,611,000
Price Date	2026-05-08
Price EBITDA	$112
Relative Volume	1.02x
Revenue	803,794,000x
SBC By Revenue	2.41x
Share Based Comp	19,350,000
Tax By Revenue	0.23x
Tr6m	9.99%
Volume	199,028
Z Score	4.4

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does TLX pay a dividend?

Capital-return profile for this ticker.

Performance

TLX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns TLX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+46.5%

Float: +80.5% of shares outstanding

Insider ownership

+14.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

TLX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

56.6

Neutral momentum band

Price vs 200-day MA

+13.0%

50/200-day relationship not available

Beta (5Y)

0.61

Less volatile than the market

Sharpe ratio

-0.66

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About TLX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current TLX stock rating?

Telix Pharmaceuticals Limited is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full TLX analysis?

The full report lives at /stocks/TLX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for TLX?

The latest report frames TLX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the TLX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.